UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock CODX The Nasdaq Capital Market Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☒ Emerging growth company ☒ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR ...

Co-Diagnostics, Inc. (NASDAQ:CODX) Q4 2021 Results Conference Call March 24, 2022 4:30 PM ET Company Participants Andrew Benson - Head, IR Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Yi Chen - H.C. Wainwright Jim Sidoti - Sidoti & Company Theodore O’Neill - Litchfield Hills Research Operator Good day, and welcome to the Co-Diagnostics, Inc. Fourth Quarter and Full Year 2021 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_______to_______ Commission File Number 001-38148 CO-DIAGNOSTICS, INC. | --- | --- | --- | |----------------------------------------------------------------------- ...

Call Start: 16:30 January 1, 0000 5:15 PM ET Co-Diagnostics, Inc. (NASDAQ:CODX) Q3 Earnings Conference Call November 09, 2021, 04:30 PM ET Company Participants Andrew Benson – Head of Investor Relations Dwight Egan – Chief Executive Officer Brian Brown – CFO Conference Call Participants Yi Chen – H.C Unidentified Speaker – Maxim Group Theodore O'Neill – Litchfield Hills Research Operator Good afternoon and welcome to the Co-Diagnostics Q3 2021 Earnings Call. All participants will be in listen-only mode. Wh ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock CODX The Nasdaq Capital Market Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☒ Emerging growth company ☒ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 1 ...

Financial Data and Key Metrics Changes - In Q2 2021, revenue reached $27.4 million, an increase of $3.3 million or 13.8% from $24 million in Q2 2020, primarily driven by continued sales of the Logix Smart COVID-19 test [26] - Gross profit for the quarter increased by $6.8 million or 37.6% to $24.9 million, up from $18.1 million in the same quarter last year [26] - Year-to-date revenue grew to $47.4 million, an increase of $21.8 million or 85.2%, with gross profit up more than 100% to $41.6 million [28] Business Line Data and Key Metrics Changes - The company achieved record sales in Q2, with international sales exceeding domestic sales, reflecting strong international partnerships [9] - CoSara, the joint venture in India, reported a profitable quarter driven by demand for COVID-19 tests and other diagnostics [12] - The company plans to expand its product offerings to serve the centralized laboratory segment and the at-home and point-of-care market with the Eikon platform [14] Market Data and Key Metrics Changes - The demand for COVID-19 testing remains strong due to the emergence of variants and the need for ongoing testing despite widespread vaccination [20][21] - The company has sold over 20 million Logix Smart COVID-19-related products, indicating robust market demand [10] - The company anticipates third-quarter revenue between $23 million and $25 million, reflecting continued strong domestic and international demand [38] Company Strategy and Development Direction - The company aims to become a leading global molecular diagnostics company, leveraging its clean balance sheet and strong cash accumulation [9] - The Eikon platform is designed to operationalize testing in at-home and point-of-care settings, with a focus on speed, accuracy, and cost-effectiveness [24] - The company is expanding its menu of tests beyond COVID-19 to include various infectious diseases and cancer detection [17] Management's Comments on Operating Environment and Future Outlook - Management believes that mass vaccination will not eliminate the need for testing, emphasizing the importance of ongoing testing in various settings [20][21] - The company is optimistic about the potential contribution of the Eikon platform to future growth, with plans for regulatory submissions in Q4 [48] - Management expressed confidence in the company's ability to generate solid financial results for the second half of 2021 [37] Other Important Information - The company reported total operating expenses of $13.1 million for Q2, up from $3.4 million in the same quarter last year, driven by increased sales and marketing and R&D expenses [28] - The balance sheet strengthened with cash, cash equivalents, and marketable securities totaling $72.4 million at June 30, 2021, an increase of $25 million from December 31, 2020 [34] - The company has no debt, allowing it to focus on launching the Eikon product without financial distractions [55] Q&A Session Summary Question: Long-term view of COVID-19 diagnostic market demand - Management believes that testing will continue to be necessary despite widespread vaccination, especially with the emergence of new variants [41][42] Question: Current estimated timeframe for Eikon to enter the market - The company anticipates submitting for FDA EUA by the end of Q4 2021, with ongoing clinical trials [48][49] Question: Plans for cash reserves - The company intends to use its cash reserves to support the ambitious international launch of the Eikon product [55] Question: Dynamics behind sales fall-off in the U.S. - The decline in U.S. sales is attributed to widespread vaccination and the normalization of activities, but ongoing testing remains essential due to variants [61][63]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock CODX NASDAQ-CM Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☒ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SEC ...

Financial Data and Key Metrics Changes - Revenue for Q1 2021 increased to $20.0 million from $1.5 million in Q1 2020, primarily due to continued sales of the Logix Smart COVID-19 test [47] - Gross profit rose from $1.1 million in Q1 2020 to $16.8 million in Q1 2021, representing 83.7% of consolidated revenue [47] - Net income for Q1 2021 was $7.9 million or $0.26 per fully diluted share, compared to a net loss of $1.1 million in Q1 2020 [50] Business Line Data and Key Metrics Changes - Sales of COVID-19 tests continued to drive overall sales momentum, with strong demand expected to persist [11][20] - The ABC test's share of testing orders increased from 1% in Q4 2020 to 5% in Q1 2021 and 14% in Q2 2021 [31] Market Data and Key Metrics Changes - The company anticipates a shift towards international sales, with expectations of a 40% domestic and 60% international revenue mix by the end of 2021 [78] - The global market for liquid biopsy testing is expected to grow from over $1 billion in 2019 to over $5 billion by 2027 [59] Company Strategy and Development Direction - The company is focused on expanding its international footprint and leveraging its CoPrimer technology to develop a broader range of diagnostic products [55][58] - The Eikon testing platform is positioned as a revolutionary product that will enable rapid, low-cost PCR testing in various settings, including at home [40][86] Management's Comments on Operating Environment and Future Outlook - Management noted that while vaccination rates are rising in the U.S., global infection rates remain high, indicating ongoing demand for testing [14][19] - The company is optimistic about its long-term prospects, driven by a growing suite of molecular diagnostics and the introduction of the Eikon platform [97] Other Important Information - The company ended Q1 2021 with cash, cash equivalents, and marketable securities totaling $60.1 million, an increase of $12.8 million from the previous quarter [51] - The company has no debt and is well-capitalized, allowing for continued investment in growth opportunities [52] Q&A Session Summary Question: Is CoSara operation in any way negatively impacted by the pandemic in India? - Management confirmed that while there were periods of lockdown affecting personnel, the operation itself has been able to meet demand for tests [73][74] Question: Do you expect to maintain the gross margin demonstrated in the first quarter going forward? - Management indicated that while some pricing pressures are expected, they anticipate maintaining a similar gross margin [75] Question: Do you foresee the export of COVID tests to ex-U.S. territories being a major revenue driver in 2021? - Management expressed confidence in the growth of international business and the anticipated shift towards a higher percentage of international sales [78] Question: Are you considering any other potential partnership opportunities outside of the U.S.? - Currently, there are no new joint ventures being explored outside of the U.S., with a focus on expanding the existing CoSara partnership in India [80] Question: Is the Eikon testing platform essentially a lab in a box for home use? - Management described the Eikon platform as a unique, compact device that allows for self-administered testing with results delivered in under 30 minutes [86][88]

[PART I FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) The company's Q1 2021 financial statements reflect significant performance improvement, with revenue surging and net income turning positive [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2021, the balance sheet reflects strong liquidity, with total assets of $81.1 million and cash increasing to $57.8 million Condensed Consolidated Balance Sheet Highlights (Unaudited) | Metric | March 31, 2021 ($) | December 31, 2020 ($) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $57,788,893 | $42,976,713 | | Total current assets | $79,134,597 | $68,360,433 | | Total assets | $81,118,971 | $71,237,197 | | **Liabilities & Equity** | | | | Total current liabilities | $4,306,693 | $4,510,688 | | Total liabilities | $4,861,495 | $4,540,688 | | Accumulated earnings | $25,409,690 | $17,510,715 | | Total stockholders' equity | $76,257,476 | $66,696,509 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q1 2021 revenue significantly increased to $20.0 million, leading to a gross profit of $16.8 million and a turnaround to a net income of $7.9 million Statement of Operations Summary (Unaudited) | Metric | Three Months Ended March 31, 2021 ($) | Three Months Ended March 31, 2020 ($) | | :--- | :--- | :--- | | Revenue | $20,024,769 | $1,548,528 | | Gross Profit | $16,752,204 | $1,066,788 | | Income (loss) from operations | $10,334,901 | ($1,081,949) | | Net income (loss) | $7,898,975 | ($1,065,193) | | Diluted EPS ($) | $0.26 | ($0.05) | [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) The company generated $12.3 million in cash from operating activities in Q1 2021, significantly improving cash and cash equivalents to $57.8 million Cash Flow Summary (Unaudited) | Metric | Three Months Ended March 31, 2021 ($) | Three Months Ended March 31, 2020 ($) | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $12,269,955 | ($1,335,528) | | Net cash provided by (used in) investing activities | $2,393,244 | ($250,370) | | Net cash provided by financing activities | $148,981 | $18,062,083 | | Net increase in cash and cash equivalents | $14,812,180 | $16,476,185 | | Cash and cash equivalents at end of period | $57,788,893 | $17,369,323 | [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail accounting policies, revenue recognition, and other financial items, highlighting customer concentration, geographic revenue shifts, and ongoing securities class action lawsuits - The company's business involves developing, manufacturing, and selling reagents for molecular diagnostic tests for infectious diseases, cancer screening, and agricultural applications[18](index=18&type=chunk) - Significant customer concentration exists, with three customers accounting for approximately **57%** of total revenue for the three months ended March 31, 2021. Two customers accounted for **61%** of accounts receivable[39](index=39&type=chunk) Revenue by Geographic Area | Region | Q1 2021 Revenue ($) | Q1 2020 Revenue ($) | Q1 2021 % of Total | Q1 2020 % of Total | | :--- | :--- | :--- | :--- | :--- | | United States | $12,493,950 | $614,025 | 62% | 40% | | Rest of World | $7,530,819 | $934,503 | 38% | 60% | | **Total** | **$20,024,769** | **$1,548,528** | **100%** | **100%** | - The company is defending against securities class action complaints filed in July and September 2020, which allege false and misleading press releases. The company believes the lawsuits are without merit but is unable to estimate a range of potential loss[73](index=73&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=17&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes Q1 2021 revenue and profitability growth to LogixSmart COVID-19 test sales, with increased R&D for a new point-of-care device, and maintains strong liquidity - The company has initiated a project to develop a low-cost, easy-to-use testing device for frequent COVID-19 screening that can provide PCR-quality results in less than an hour, targeting schools, businesses, and home use[93](index=93&type=chunk) - The increase in revenue of **$18.5 million** in Q1 2021 compared to Q1 2020 was primarily due to sales of the LogixSmart COVID-19 test[94](index=94&type=chunk) - Research and development expenses increased by **$1.8 million** year-over-year, driven by over **$1 million** in expenditures for the new point-of-care device and increased personnel costs[100](index=100&type=chunk) - As of March 31, 2021, the company had a strong liquidity position with **$57.8 million** in cash and cash equivalents and believes it has sufficient capital for the next 12 months of operations[103](index=103&type=chunk)[109](index=109&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=21&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) Disclosure is not required as the company qualifies as a 'smaller reporting company' under Regulation S-K - Disclosure is not required for "smaller reporting companies"[113](index=113&type=chunk) [Item 4. Controls and Procedures](index=21&type=section&id=Item%204.%20Controls%20and%20Procedures) As of March 31, 2021, disclosure controls and procedures were deemed effective, with a new CFO appointed in February 2021 - Management concluded that the company's disclosure controls and procedures were **effective** as of March 31, 2021[113](index=113&type=chunk) - On February 22, 2021, Brian L. Brown was appointed as the company's Chief Financial Officer[114](index=114&type=chunk) [PART II OTHER INFORMATION](index=22&type=section&id=PART%20II%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=22&type=section&id=Item%201.%20Legal%20Proceedings) No material developments occurred in previously disclosed legal proceedings, and the company has responded to inquiries from FINRA, NASDAQ, and the SEC - No material developments have occurred in the legal proceedings previously disclosed in the company's Annual Report on Form 10-K[117](index=117&type=chunk) - The company has received and responded to inquiries from FINRA, NASDAQ, and the SEC[118](index=118&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=22&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company issued 1,258 shares of common stock on April 6, 2021, for consulting services under an unregistered exemption - On April 6, 2021, the company issued **1,258 shares** of common stock for consulting services[120](index=120&type=chunk) [Item 3. Defaults Upon Senior Securities](index=23&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities - None[122](index=122&type=chunk) [Item 4. Mine Safety Disclosures](index=23&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[123](index=123&type=chunk) [Item 5. Other Information](index=23&type=section&id=Item%205.%20Other%20Information) The company reported no other information - None[124](index=124&type=chunk) [Item 6. Exhibits](index=23&type=section&id=Item%206.%20Exhibits) This section indexes exhibits filed with Form 10-Q, including CEO and CFO certifications and XBRL interactive data files - The report includes CEO and CFO certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act[125](index=125&type=chunk) - XBRL Instance Document and related taxonomy files are included as exhibits[125](index=125&type=chunk)

Co-Diagnostics, Inc. (NASDAQ:CODX) Q4 2020 Results Earnings Conference Call March 25, 2021 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chairman, CEO & President Brian Brown - CFO Reed Benson - Secretary & General Counsel Conference Call Participants Yi Chen - H.C. Wainwright Theodore O'Neill - Litchfield Hills Research Operator Good afternoon, and welcome to the Co-Diagnostics Fourth Quarter and Full Year 2020 Earnings Conference Call. All participants will be in ...